



# Proinflammatory enzyme soluble epoxide hydrolase bridges obesity to colonic inflammation and potential carcinogenesis

Guang-Yu Yang<sup>a,1</sup>

## Soluble Epoxide Hydrolase: A Mechanistic Link Between Obesity and Colonic Inflammation

Obesity and chronic inflammation are two well-recognized risk factors for the development of colorectal cancer (CRC). In PNAS, Wang et al. (1) use lipidomic profiling analysis to identify a significant mechanistic link between obesity and colonic inflammation via enhancing the proinflammatory enzyme soluble epoxide hydrolase (sEH).

## The Potential Role of Soluble Epoxide Hydrolase in Obesity-Promoted Colorectal Carcinogenesis

The aberrant metabolism of polyunsaturated fatty acids, and particularly arachidonic acid, is thought to be a key inflammatory mediator contributing to colorectal carcinogenesis. The role of cytochrome P450 epoxygenase in this metabolism, though, and the role of its epoxy fatty acid metabolites in obesity and CRC are not well known. Endogenous epoxide fatty acid(s) have highly polarized oxygen-carbon bonds, making them crucial signaling molecules/metabolites. It is well known that these epoxy fatty acids have antiinflammatory effects, but physiologically epoxide fatty acid metabolites are quickly inactivated by sEH. As such, sEH is considered a proinflammatory enzyme.

Wang et al. (1) sequentially demonstrate that (i) there is an increased expression of sEH and its eicosanoid metabolites in the colons of high-fat-diet-induced obese mice and (ii) the knockout or inhibition of sEH ablates obesity-induced colonic inflammation and decreases obesity-induced activation of Wnt signaling. This study raises interest in further investigating whether the ablation of obesity-induced colonic inflammation by sEH knockout or inhibition may lead to inhibition of obesity-promoted colorectal carcinogenesis (2, 3).

## Counterbalancing Nonsteroidal Antiinflammatory Drugs-Related Adverse Effects via Targeting Soluble Epoxide Hydrolase

Thus far, nonsteroidal antiinflammatory drugs (NSAIDs) and Cyclooxygenase 2 (COX-2) inhibitor (coxibs) have been the most promising agents for the prevention of CRC (4). However, the side-effect profile and risk of adverse events including gastrointestinal bleeding and cardiovascular events frequently prohibit their widespread clinical use (5, 6). The cardiovascular risks associated with coxibs are due to an imbalance in the production of prostacyclin I<sub>2</sub> (PGI<sub>2</sub>, platelet aggregation inhibitor) and thromboxane A<sub>2</sub> (TXA<sub>2</sub>, platelet activator) and the accumulation of 20-hydroxyeicosatetraenoic acids (20-HETE, a vasoconstrictor), which increase arterial blood pressure (4, 6, 7). The adverse events of NSAIDs/coxibs may be counterbalanced by epoxy-eicosanoid metabolites such as epoxyeicosatrienoic acids (EETs) (7). EETs are known to attenuate inflammation and hypertension and to enhance wound/ulcer healing by (i) suppressing cytokine-induced vascular cell adhesion molecules and chemokine-induced chemotaxis (8–10), (ii) reducing TXA<sub>2</sub> and 20-HETE-mediated platelet aggregation (7, 11, 12), (iii) reducing blood pressure (13), and (iv) inhibiting inflammation and enhancing angiogenesis for wound healing (14–16). Therefore, cotargeting sEH and COX-2 to manipulate eicosanoid metabolites has the high potential to synergistically enhance the inhibition of obesity-promoted inflammation and carcinogenesis while also reducing the adverse effects of coxibs and NSAIDs.

## Acknowledgments

This study was supported by NIH Grants R01 DK10776, CA172431, and CA164041 (to G.-Y.Y.).

<sup>a</sup>Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611

Author contributions: G.-Y.Y. wrote the paper.

The author declares no conflict of interest.

Published under the PNAS license.

See companion article on page 5283 in issue 20 of volume 115.

<sup>1</sup>Email: g-yang@northwestern.edu.

Published online May 16, 2018.

- 1 Wang W, et al. (2018) Lipidomic profiling reveals soluble epoxide hydrolase as a therapeutic target of obesity-induced colonic inflammation. *Proc Natl Acad Sci USA* 115:5283–5288.
- 2 Zhang W, et al. (2012) Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice. *Dig Dis Sci* 57:2580–2591.
- 3 Zhang W, et al. (2013) Reduction of inflammatory bowel disease-induced tumor development in IL-10 knockout mice with soluble epoxide hydrolase gene deficiency. *Mol Carcinog* 52:726–738.
- 4 Fischer SM, Hawk ET, Lubet RA (2011) Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. *Cancer Prev Res (Phila)* 4:1728–1735.
- 5 Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. *N Engl J Med* 340:1888–1899.
- 6 Sudano I, et al. (2012) Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension. *Curr Hypertens Rep* 14:304–309.
- 7 Liu JYL, et al. (2010) Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. *Proc Natl Acad Sci USA* 107:17017–17022.
- 8 Node K, et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. *Science* 285:1276–1279.
- 9 Norwood S, Liao J, Hammock BD, Yang GY (2010) Epoxyeicosatrienoic acids and soluble epoxide hydrolase: Potential therapeutic targets for inflammation and its induced carcinogenesis. *Am J Transl Res* 2:447–457.
- 10 Kundu S, et al. (2013) Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo. *J Lipid Res* 54:436–447.
- 11 Fitzpatrick FA, et al. (1986) Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. *J Biol Chem* 261:15334–15338.
- 12 Matsumoto N, Suzuki E, Ishikawa M, Shirafuji T, Hasumi K (2014) Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7. *J Biol Chem* 289:35826–35838.
- 13 Imig JD, Hammock BD (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. *Nat Rev Drug Discov* 8:794–805.
- 14 Sander AL, et al. (2011) Cytochrome P450-derived epoxyeicosatrienoic acids accelerate wound epithelialization and neovascularization in the hairless mouse ear wound model. *Langenbecks Arch Surg* 396:1245–1253.
- 15 Panigrahy D, et al. (2013) Epoxyeicosanoids promote organ and tissue regeneration. *Proc Natl Acad Sci USA* 110:13528–13533.
- 16 Sander AL, et al. (2013) Soluble epoxide hydrolase disruption as therapeutic target for wound healing. *J Surg Res* 182:362–367.